Navigation Links
Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
Date:8/19/2007

mpany reported a net loss of $8.2 million, or $0.27 per share, for the second quarter of 2007, compared to a net loss of $14.6 million, or $0.66 per share, for the second quarter of 2006. For the six months ended June 30, 2007, the Company reported a net loss of $13.8 million, or $0.48 per share, compared to a net loss of $24.5 million, or $1.17 per share, for the comparable period in 2006.

Net product sales of Ganite in the second quarter and first six months of 2007 of $0.1 million and $0.2 million, respectively, declined from the prior- year periods of $0.4 million and $0.4 million, respectively. The second quarter of 2006 included the effects of a reduction in the provision for Ganite sales returns of $0.3 million. Excluding this adjustment, sales slightly increased in the second quarter and first six months of 2007. Operating expenses declined in the second quarter and first six months of 2007, as the prior year included a buildup of sales, marketing and manufacturing expenses incurred in preparation for a possible commercial launch of Genasense. In addition, lower expenses in 2007 reflect the impact of a staff reduction in December 2006.

In the fourth quarter of 2006, the Company recorded an expense of $5.3 million that provides for the issuance of 2 million shares of Genta common stock, for a settlement in principle of class action litigation. The expense is net of insurance recovery of $18.0 million. At June 30, 2007, the revised estimated value of the common shares portion of the litigation settlement is $3.5 million, based on a closing price of Genta's common stock of $1.74 per share, resulting in a reduction in the provision of $0.2 million in the second quarter and a reduction of $1.8 million for the first six months of 2007.

As of June 30, 2007, Genta had no long-term debt, $0.2 million in short- term debt, and had cash, cash equivalents and marketable securities of $22.4 million, compared to $29.5 million as of December 31, 2006. Duri
'/>"/>

SOURCE Genta Incorporated

Copyright©2007 PR Newswire.

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Genta Announces Results of Phase 1 Study Using Genasense Administered by Intermittent Subcutaneous Injection
2. Genta Incorporated to Present Multiple Abstracts at the Annual Meeting of the American Society of Clinical Oncology
3. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
4. Sygnis Pharma AG announces date for presentation of clinical results
5. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
7. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
8. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
9. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
10. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
11. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)...   Synageva BioPharma Corp. (NASDAQ: ... products for rare disorders, today announced validation by ... Authorization Application (MAA) for sebelipase alfa for LAL ... for accelerated assessment, which has the potential to ... The MAA, and the Biologics License Application ...
(Date:12/24/2014)...  The American Diabetes Association is recommending a ... with diabetes and that all people with diabetes ... in keeping with recent changes to guidelines for ... of Cardiology (ACC) and American Heart Association (AHA). ... changes to the Association,s annual revised Standards of ...
(Date:12/24/2014)... , Dec. 23, 2014  Endo Pharmaceuticals Inc., ... ENDP ) (TSX: ENL), and BioDelivery Sciences International, Inc. ... have submitted a New Drug Application (NDA) for Buprenorphine ... Administration (FDA).  Buprenorphine HCl Buccal Film is under development ... daily, around-the-clock, long-term opioid treatment and for which alternative ...
Breaking Medicine Technology:Synageva BioPharma Announces Sebelipase Alfa Marketing Authorization Application Validated By The EMA 2Synageva BioPharma Announces Sebelipase Alfa Marketing Authorization Application Validated By The EMA 3New Standards of Care Provide Guidelines for Statin Use for People with Diabetes to Prevent Heart Disease 2New Standards of Care Provide Guidelines for Statin Use for People with Diabetes to Prevent Heart Disease 3New Standards of Care Provide Guidelines for Statin Use for People with Diabetes to Prevent Heart Disease 4Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 2Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 3Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 4Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 5
(Date:12/26/2014)... Phoenix, AZ (PRWEB) December 26, 2014 ... dependable source for the best in heating, cooling ... demand for 24 hour emergency services in 2014 ... customers alike know that Arizona is known for ... contractor company that understands the intricacies and details ...
(Date:12/25/2014)... Dallas, TX (PRWEB) December 26, 2014 ... and Market Analysis to 2023” focuses on the ... commercial opportunities in the colorectal cancer market. Stivarga ... treatment of colon or rectal cancer. Boehringer Ingelheim ... inhibitor, for the treatment of refractory CRC in ...
(Date:12/25/2014)... 26, 2014 Recently, iFitDress.com, the popular online ... has announced its new selection of black one-shoulder cocktail ... sale now; they are available at discounted prices, up to ... promotion will last for three weeks only. You know, we ... who are interested in our new items can visit our ...
(Date:12/25/2014)... (PRWEB) December 25, 2014 BambooFlooringChina.com sells ... high quality bamboo flooring. Today, the company announces ... in many styles and colors. , BambooFlooringChina.com is the ... CEO, the promotion is valid until Jan. 20, 2015. ... strips and woven with a natural thread. All the ...
(Date:12/25/2014)... Dennis Thompson HealthDay Reporter ... with complex chronic illnesses can receive effective, less expensive care ... easy access to a team of dedicated health care professionals, ... become seriously ill and need either hospitalization or a trip ... enhanced medical home clinic at the University of Texas in ...
Breaking Medicine News(10 mins):Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 2Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 3Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 4Health News:iFitDress.com: Black One-Shoulder Cocktail Dresses for 2015 2Health News:Various Styles of Bamboo Mats in Many Colors from BambooFlooringChina.com 2Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 2Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 3
... Certain types of anti-smoking ads may not be effective for ... new study. University of Georgia researchers found that these ... smoking can lead to disease and death and how secondhand ... messages, there is usually a threat trying to make you ...
... from The Neuroscience Institute at NYU Langone Medical Center ... at the Society for Neuroscience 41st Annual Meeting in ... presents an opportunity for leading scientists from around the ... treating diseases and conditions of the brain," said Richard ...
... Liverpool and the universities of California, Berkley and del ... among young children are reduced by one-third in homes ... published in the Lancet , highlighted the health ... dirty cooking stoves, the primary source of cooking and ...
... using stem cells, in the hope to replace damaged ... for application in other degenerative conditions. Drs Clare ... Florey Neuroscience Institutes and the University of Melbourne. They ... collaboration being launched at the University of Melbourne today. ...
... By Steven Reinberg HealthDay Reporter , THURSDAY, Nov. ... about 20 percent of Americans still light up, but almost ... "This study is reassuring to us," Dr. Tim McAfee, ... U.S. Centers for Disease Control and Prevention, said during a ...
... Eating a high-fiber diet may reduce your risk of colorectal ... grains, according to a new review. British and ... nearly 2 million people. Compared with the lowest levels of ... of total dietary fiber and cereal fiber was associated with ...
Cached Medicine News:Health News:Negative Anti-Smoking Ads Turn Off Anxious Viewers 2Health News:Woodsmoke from cooking fires linked to pneumonia 2Health News:Stem cell research hopes to repair brain damage of Parkinson's disease 2Health News:Stem cell research hopes to repair brain damage of Parkinson's disease 3Health News:Most Smokers Want to Quit, CDC Report Finds 2Health News:Most Smokers Want to Quit, CDC Report Finds 3Health News:Most Smokers Want to Quit, CDC Report Finds 4Health News:High-Fiber Diet May Help Thwart Colon Cancer 2
... fixed pipette is ideal for ... volume. Fixed volume FInnpipettes offer ... as other Finnpipette Digital pipettes: ... blow-out (1-40ul), Soft-touch tip ejection, ...
... The new Finnpipette Focus ... specifically to combine ergonomics with ... interchangeable handle plate offers a ... sizes. The new shorter tip ...
... The new Finnpipette Focus from ... to combine ergonomics with uncompromising ... handle plate offers a custom ... The new shorter tip cones ...
... Pipette is a synonym for pipetting accuracy, ... design, and superior operating comfort. Its single, ... measuring stroke and blow-out as well as ... ensures utmost accuracy and precision. Ejection sleeve ...
Medicine Products: